A Phase 1a/1b, Dose-Ranging Study of the Safety, Tolerability, Pharmacokinetics, and Initial Efficacy of ABI-H0731 in Healthy Volunteers and Patients With Chronic Hepatitis B

Trial Profile

A Phase 1a/1b, Dose-Ranging Study of the Safety, Tolerability, Pharmacokinetics, and Initial Efficacy of ABI-H0731 in Healthy Volunteers and Patients With Chronic Hepatitis B

Recruiting
Phase of Trial: Phase I

Latest Information Update: 02 Oct 2017

At a glance

  • Drugs ABI-H0731 (Primary) ; Entecavir; Tenofovir disoproxil fumarate
  • Indications Hepatitis B
  • Focus Adverse reactions
  • Sponsors Assembly Biosciences
  • Most Recent Events

    • 02 Oct 2017 Results published in an Assembly Biosciences media release.
    • 02 Oct 2017 According to an Assembly Biosciences media release, data from the study will be presented at the upcoming Annual Meeting of the American Association for the Study of Liver Diseases (AASLD).
    • 25 Sep 2017 According to an Assembly Biosciences media release, phase 1a portion of the trial has been completed during early 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top